Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, open-label, multiple-dose study of BMS-663068 ± ritonavir in HIV-1 infection
2009-013657-14Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Antiviral activity of BMS-626529/BMS-663068 and Safety and tolerability of BMS-663068 ± ritonavir. Started Sep 2009; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-013657-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013657-14.